332 results about "Abnormal expression" patented technology

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

PROBLEM

There are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells.

MEANS FOR SOLVING

An induced malignant stem cell capable of in vitro proliferation are characterized by satisfying the following two requirements:

• (1) having at least one aberration selected from among (a) an aberration of methylation (high or low degree of methylation) in a tumor suppressor gene or a cancer-related genetic region in endogenous genomic DNA, (b) a somatic mutation of a tumor suppressor gene or a somatic mutation of an endogenous cancer-related gene in endogenous genomic DNA, (c) abnormal expression (increased or reduced/lost expression) of an endogenous oncogene or an endogenous tumor suppressor gene, (d) abnormal expression (increased or reduced/lost expression) of a noncoding RNA such as an endogenous cancer-related microRNA, (e) abnormal expression of an endogenous cancer-related protein, (f) an aberration of endogenous cancer-related metabolism (hypermetabolism or hypometabolism), (g) an aberration of endogenous cancer-related sugar chain, (h) an aberration of copy number variations in endogenous genomic DNA, and (i) instability of microsatellites in endogenous genomic DNA in an induced malignant stem cell; and
• (2) expressing genes including POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

The invention discloses a thieno 2,4-substituted pyrimidine compound of which the general formulas are (I), (II), (III) and (IV), or pharmaceutically acceptable salt or stereisomer or a prodrug molecule, and a pharmaceutical composition and application thereof. The thieno 2,4-substituted pyrimidine compound can effectively restrain abnormal expression of Aurora kinase, has specific inhibited effect on Aurora-A and Aurora-B, can be applied to a novel field of molecular targeting treatment, and has strong inhibitory activity on an excessive hyperplasia disease, especially cervical tumor cells, human macrophage line leukemia cell, and human t-lymphocyte line cancer cell.

The invention discloses a CRISPR-Cas9 system for knocking out the gene GRIN2D and its application. The CRISPR-Cas9 system comprises Cas9 and gRNA specifically targeting to the gene GRIN2D. The invention also discloses application of the CRISPR-Cas9 system to preparation of drugs used for treating cancer and application of the gene GRIN2D to diagnostic kits and medicines used for precise treatmentof stomach cancer and other tumors. In virtue of a clinical sample tissue chip of stomach cancer, the gene GRIN2D is proved to be increased in expression in stomach cancer tissue and be related to prognosis according to immunohistochemical results. The CRISPR-Cas9 system provided by the invention can highly efficiently knock out the highly-expressed gene GRIN2D in stomach cancer and inhibit the proliferation and migration/invasion of gastric cancer cells, and is simple to operate and high in knockout efficiency. The CRISPR-Cas9 system is expected to be applied to diagnosis and treatment of stomach cancer and other tumors with over-expressed GRIN2D. The CRISPR-Cas9 system is applicable to a plurality of tumors with abnormal expression of GRIN2D.

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

The invention relates to the field of biotechnology, in particular to an anti-EGFR (epidermal growth factor receptor) and anti-CD3 (cluster of differentiation 3) bispecific antibody and an application thereof. The bispecific antibody can be specifically bound with EGFR of tumor cell surface antigens and CD3, namely, CD3 molecules, of immune cell surface antigens; a single-chain antibody ScFv of an anti-CD3 antibody is located at the C terminal of a constant region of an anti-EGFR antibody. The invention further provides a preparation method of the bispecific antibody and a clinical application of the bispecific antibody. The bispecific antibody has higher affinity and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by EGFR overexpression.

The invention discloses a substituted purin-9-acetamino isohydroxamic acid histone deacetylase inhibitor and a preparation method and application thereof. The inhibitor has the structure as shown in formula I described in the specification. The inhibitor disclosed by invention has strong inhibitory activity on HDAC (histone deacetylase) and can be used for the prevention or treatment of related mammalian diseases caused by abnormal expression of histone deacetylase. The invention also relates to an application of the inhibitor having the general formula I in preparing the medicines.

The invention provides nine micro RNA (Ribonucleic Acid) (miRNA) molecular markers for diagnosing rheumatoid arthritis and an application thereof to a detection kit. The miRNA molecular markers have abnormal expression in blood of patients with the rheumatoid arthritis to diagnose the rheumatoid arthritis; the miRNA molecular marker has high combination sensitivity and specificity; materials are convenient to fetch; the miRNA molecular marker is safe and noninvasive and provides important evidences to early diagnosis of diseases and disease course monitoring. The invention further provides a kit for diagnosing the rheumatoid arthritis and the application of the miRNA molecular marker to the diagnosing kit. The kit is characterized by comprising the combination of the nine miRNA molecular markers for detecting blood plasma and a reagent for detecting the nine miRNA molecular markers.

The invention discloses a multi-feature fusion driver abnormal expression recognition method. The multi-feature fusion driver abnormal expression recognition method comprises the steps: S1, tracking and monitoring expression actions of a driver in real time through a camera installed on the driver side; S2, precisely identifying expression details in the real-time driver video; S3, detecting the positions of the eyes, and judging whether the eyes are tired or not; S4, positioning the edge contour of the mouth, and judging whether yawn action occurs or not; S5, detecting a head action, and judging whether fatigue occurs or not; S6, weighting the detection results of the eye state, the mouth state and the head motion state, finally judging whether fatigue occurs or not, and outputting the detection results; and S7, combining the identification result of the current frame as an estimated position of subsequent frame identification, and respectively detecting actions in subsequent frames to realize continuous detection and identification of abnormal behaviors of the driver. According to the invention, real-time monitoring and alarm triggering can be carried out, a driver is warned andreminded, and traffic accidents are prevented, and the safety in the driving process is ensured.

The applicant provides a long-chain non-coding lncRNA-OD1 which is formed by transcribing a gene located at a chromosome 18: chr18: 77343316-77345492, hg19, and the length of the gene sequence is 2177bp. The applicant also provides application of the long-chain non-coding lncRNA-OD1 in preparation of a reagent, a kit or a gene chip for predicting osteoporosis. In the invention, through a gene chip technology, a bioinformatics technology and a molecular biological technology, whether abnormal expression occurs in an LncRNA in an osteoporosis process can be determined, and the function of the LncRNA in the pathogenetic process of osteoporosis is understood, so that a new clue is provided for early diagnosis of osteoporosis, and a molecular mechanism of occurrence of osteoporosis is enriched favorably.

The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.

The present invention provides novel antibodies immunospecifically binding to IL-9 polypeptides and compositions comprising the antibodies. The present invention also provides a method for preventing, treating, controlling and/or improving diseases and disorders related to abnormal expression and/or activity of IL-9 or IL-9 receptor or its subunits, autoimmune diseases, inflammatory diseases, A method for proliferative diseases and infections comprising administering one or more antibodies that immunospecifically bind to IL-9 polypeptide. The present invention also includes methods and compositions for diagnosing, monitoring and prognosing said disorders. The invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to IL-9 polypeptides.

The invention establishes a circRNA expression profile for a patient with craniosynostosis, provides, provides serum circRNA marker hsa_circ_0001788 for the patient with craniosynostosis, discloses diagnostic value of hsa_circ_0001788 of serum for craniosynostosis, applies the marker herein to prepare a diagnostic kit for the patient with craniosynostosis, and provides supporting for clinical early discovery and treatment of the patient with craniosynostosis. Serum circRNA has good stability, degradation difficulty and the other advantage, has high value in auxiliary diagnosis, and is easy toclinically popularize and use. A circRNA chip is used herein to carry out detecting to obtain disease-specific and abnormally-expressed serum circRNA expression profiles; verifying is performed by means of qRT-PCR; a strict design and evaluation system is provided. It is discovered for the first time that the marker hsa_circ_0001788 in serum is an important biological detection index which causesminimal invasion and has low cost and which is applicable to clinical detection; the marker hsa_circ_0001788 is important to the clinical early diagnosis and differential diagnosis of craniosynostosis; a new idea is provided for the diagnosis of craniosynostosis in molecular level, and it is expected that early diagnostic rate of craniosynostosis is increased.